Nephron Announces FDA Approval of Ketorolac, Signaling New Phase of Growth Kennedy: Company Excited to Expand Generic Portfolio to Include Non-Respiratory Products News provided by Share this article WEST COLUMBIA, S.C., Dec. 22, 2020 /PRNewswire/ -- Nephron Pharmaceuticals Corporation is celebrating another milestone. The company today announced Food and Drug Administration (FDA) approval of the Nephron Abbreviated New Drug Application (ANDA) for Ketorolac Tromethamine Injection USP, 60 mg/2 mL (30 mg/mL) in Single-Dose Vials. The vials are made of polypropylene plastic with a "luer lock" interface for needle-free dosing and are manufactured using Blow-Fill-Seal (BFS) technology. Ketorolac Tromethamine becomes one of the first ANDA-approved non-respiratory generic medications produced by Nephron, signaling a new phase of company growth. Nephron secured FDA approval for Sodium Chloride IV Bags earlier this year.